Meningitis - Therapeutic Strategies

Treatment and Management of Meningitis Meningitis is a medical emergency requiring rapid diagnosis and treatment. The goal of management is twofold: eliminate the infection through targeted antimicrobial therapy and prevent complications through supportive care and adjunctive treatments. Because waiting for definitive diagnosis delays potentially life-saving treatment, empiric therapy is started immediately, then refined once the causative organism is identified. Empiric Broad-Spectrum Antibiotic Therapy The cardinal rule in meningitis management is start empiric antibiotics immediately, even before culture results are available. Delaying antibiotics while awaiting test results significantly increases mortality. This creates a tension between acting quickly and treating appropriately—the solution is to use broad-spectrum agents that cover the most common pathogens. First-line empiric agents differ slightly by region: In the United States and most high-income countries: ceftriaxone (or cefotaxime) PLUS vancomycin. The vancomycin is added because Streptococcus pneumoniae resistance to cephalosporins has increased. In the United Kingdom: cephalosporin monotherapy (cefotaxime or ceftriaxone) remains standard. Special population: add ampicillin for patients at risk of Listeria monocytogenes infection: Patients ≤2 months old (immune system too immature to produce antibodies against Listeria) Patients >50 years old Immunocompromised patients (HIV, immunosuppressants, malignancy) Listeria is resistant to cephalosporins, so ampicillin specifically must be added—it cannot be assumed that the cephalosporin regimen alone will cover this organism. Targeted Antibiotic Therapy Once the causative organism is identified (through Gram stain, culture, or molecular testing), antibiotic therapy is narrowed and optimized. This shift from empiric to targeted therapy is important because: Narrower coverage reduces side effects and resistance selection The chosen agent is specifically selected for meningeal penetration—not all antibiotics cross the blood-brain barrier effectively Tuberculous meningitis deserves special mention: it requires prolonged multidrug therapy for at least 12 months (much longer than typical bacterial meningitis). This reflects the slow growth rate of Mycobacterium tuberculosis and the need for sustained therapy to prevent relapse. Adjunctive Corticosteroids: Critical Timing and Benefits Dexamethasone (a corticosteroid) is one of the most important adjunctive therapies in bacterial meningitis. Understanding when and how to use it is essential for exam success. Timing is Everything The most critical fact: Dexamethasone must be given before or simultaneously with the first antibiotic dose. The benefit is lost if dexamethasone is given after antibiotics. This is why protocols often recommend dexamethasone be drawn up and ready to administer at the same time as the first antibiotic. What Dexamethasone Does Dexamethasone reduces inflammation in the meninges, which leads to: Reduced hearing loss (a major sequela of meningitis) Improved short-term neurologic outcomes (less brain swelling, better recovery) These benefits are most robust in high-income countries. The evidence is weaker or absent in low-income settings, possibly due to differences in nutritional status, comorbidities, or disease severity. Pathogen-Specific Benefits Dexamethasone provides the greatest benefit in pneumococcal meningitis. In Haemophilus influenzae meningitis, corticosteroids improve outcomes, but only when administered before antibiotics (timing is critical). In other bacterial causes, the benefit is less clear. Dosing and Duration Dose: Standard dexamethasone regimen (typically 10 mg IV, given as a single dose or divided doses) Duration: Continue for four days When to stop: If a non-pneumococcal cause of meningitis is definitively identified, dexamethasone can be stopped (this acknowledges that the strongest evidence is for pneumococcal disease) Supportive Care and Hemodynamic Management Fluid Management Patients with meningitis often have hemodynamic instability from infection and inflammation. Intravenous fluids are given to treat hypotension or septic shock—this is standard supportive care. A key misconception: some clinicians worry about "cerebral edema" and restrict fluids, but evidence does not support routine fluid restriction in meningitis. Fluid restriction could worsen perfusion and outcomes. Fluid management should be guided by clinical hemodynamics (blood pressure, organ perfusion), not by a blanket policy of restriction. Management of Raised Intracranial Pressure Meningitis causes inflammation that raises intracranial pressure (ICP). When ICP is elevated: Mannitol (an osmotic diuretic) or hypertonic saline can be used to reduce fluid in the brain tissue and lower ICP These are temporizing measures while definitive treatment (antibiotics, corticosteroids) takes effect Management of Specific Complications Seizures Seizures occur in approximately 20-30% of bacterial meningitis cases. They are treated with anticonvulsant drugs (such as phenytoin, levetiracetam, or others). If seizures continue despite standard anticonvulsants, they are called refractory seizures and require intensive monitoring in an ICU setting and potentially additional agents. Hydrocephalus Bacterial meningitis can cause hydrocephalus—accumulation of cerebrospinal fluid (CSF) due to obstruction of normal fluid flow. This increases ICP and neurologic deterioration. Management options include: External ventricular drainage (EVD): a temporary catheter placed in the ventricle to drain excess CSF Permanent shunting: if obstruction is permanent, a ventriculoperitoneal shunt may be needed to bypass the obstruction Respiratory Support Patients with severe meningitis may have: Decreased level of consciousness (cannot protect their airway) Direct brainstem involvement causing respiratory failure These patients require mechanical ventilation for airway protection and respiratory support. Monitoring and Supportive Care Clinical Monitoring Frequent neurological assessments are essential to detect early signs of deterioration (declining consciousness, new seizures, focal deficits) that would prompt escalation to intensive care. This is not just supportive—it guides clinical decision-making. Electrolyte Monitoring A common complication of meningitis is hyponatremia (low serum sodium), which can worsen brain swelling and seizures. Regular monitoring of sodium levels is mandatory. Hyponatremia may be due to SIADH (syndrome of inappropriate antidiuretic hormone) and may require fluid restriction or hypertonic saline, but only once it's identified through monitoring. Long-term Follow-up Bacterial meningitis survivors require follow-up assessment for sequelae, including: Hearing loss (deafness) Epilepsy Cognitive deficits Visual impairment These can emerge acutely or develop over time, making long-term follow-up important. Viral Meningitis Viral meningitis has a very different management approach from bacterial meningitis because viral infections are usually self-limited and specific antivirals are limited. General Approach: Supportive Care Most viral meningitis cases require only supportive therapy: adequate fluid intake, bed rest, and analgesics for symptom relief. The illness typically follows a benign course and resolves spontaneously over days to a week or two. Specific Antiviral Therapies For specific viruses, antiviral drugs may help: Herpes simplex virus (HSV) meningitis: treated with aciclovir (IV) Varicella-zoster virus (VZV) meningitis: treated with aciclovir (IV) These are exceptions—most other viral causes of meningitis (enterovirus, mumps, etc.) have no specific antiviral treatment. Clinical Context Mild cases of viral meningitis can often be managed at home once bacterial meningitis is excluded (typically after CSF analysis and negative bacterial cultures). This contrasts sharply with bacterial meningitis, which requires hospitalization and intensive therapy. Fungal Meningitis Fungal meningitis is rare in immunocompetent individuals but important in immunocompromised patients (especially HIV/AIDS). Cryptococcal Meningitis: The Most Common Form Cryptococcal meningitis is the most frequent fungal meningitis, particularly in patients with advanced HIV (CD4 <100 cells/μL). Unlike bacterial meningitis, fungal meningitis progresses slowly—patients may not look acutely ill despite severe infection. Antifungal Treatment The standard therapy is amphotericin B (high-dose) combined with flucytosine, given for a long duration. This combination achieves good CNS penetration and is more effective than either drug alone. Management of Raised Intracranial Pressure Raised ICP is very common in fungal meningitis and is the leading cause of death in cryptococcal meningitis. Unlike bacterial meningitis where steroids help, fungal meningitis requires active mechanical management of ICP: Daily lumbar punctures: removal of CSF through repeated LP reduces ICP Lumbar drain: an alternative to daily LP, this is a catheter placed in the lumbar space to allow continuous or periodic CSF drainage These mechanical approaches are used because the inflammation in fungal meningitis is less responsive to medical management, and the high ICP is particularly damaging in this context.